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Heterozygous germline mutations strongly predispose to leukemia,
immunodeficiency, and/or lymphoedema. We describe a series of 79 patients (53
families) diagnosed since 2011, made up of all patients in France and Belgium, with
a follow up of 2249 patients/years. Median age at first clinical symptoms was 18.6
years (range, 0-61 years). Severe infectious diseases (mycobacteria, fungus, and
human papilloma virus) and hematologic malignancies were the most common first
manifestations. The probability of remaining symptom-free was 8% at 40 years old.
Among the 53 probands, 24 had missense mutations including 4 recurrent alleles, 21
had nonsense or frameshift mutations, 4 had a whole-gene deletion, 2 had splice
defects, and 2 patients had complex mutations. There were significantly more cases
of leukemia in patients with missense mutations (n=14 of 34) than in patients with
nonsense or frameshift mutations (n=2 of 28). We also identify new features of the
disease: acute lymphoblastic leukemia, juvenile myelomonocytic leukemia, fatal
progressive multifocal leukoencephalopathy related to the JC virus, and
immune/inflammatory diseases. A revised International Prognostic Scoring System
(IPSS) score allowed a distinction to be made between a stable disease and
hematologic transformation. Chemotherapy is of limited efficacy, and has a high
toxicity with severe infectious complications. As the mortality rate is high in our
cohort (up to 35% at the age of 40), hematopoietic stem cell transplantation (HSCT)
remains the best choice of treatment to avoid severe infectious and/or hematologic
complications. The timing of HSCT remains difficult to determine, but the earlier it is
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